COMPLEX GENERICS: OPPORTUNITIES & CHALLENGES
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 3
Abstract
Now a day, big pharmaceutical companies with sustainable revenues are more interested in complex products to minimize competitions. In line with the originator companies, many generic companies are also focusing on complex products, either a specialized dosage form of already approved product or generic version of approved specialized products i.e. complex generics. Inherent ‘complexity’ involved in such specialized products insulates fierce competition and are considered as potential opportunities with high revenues. U.S FDA approved specialized products with proprietary technologies, such as nanoparticles, microspheres or liposomes are most promising dosage forms. These dosage forms are proven to be safer, while providing better efficacy as compared to historically approved simpler dosage forms, by ensuring targeted delivery of drug towards the infected cells. In the era of recent scientific advances, many generic companies are investing in abundance for the development of complex generics in the segment of targeted delivery systems like liposomes, therapeutic nanoparticles for treatment of various diseases such as cancers, inflammatory disorders, infectious and cardiovascular diseases. Despite potential opportunities reside in developing complex generics in terms of safety, efficacy and high revenue, no authoritative article has enlightened the challenges relating to regulatory, scientific, clinical, intellectual property (IP) and commercialization of complex generics. The present article makes an attempt to address the challenges involved in a regulatory approval of such complex generics involving potential opportunity with low competition.
Authors and Affiliations
Vure Prasad, Kale Pooja
Keywords
Related Articles
- EP ID EP336989
- DOI 10.22270/ijdra.v4i3.184
- Views 118
- Downloads 0
FORMULATION AND EVALUATION OF FAST DISINTEGRATING LOSARTAN POTASSIUM TABLETS BY FORMAL EXPERIMENTAL DESIGN
In the treatment of hypertension fast onset of action is the major concern. The problem of slow onset of action of drugs can be overcome by development of appropriate dosage forms. Fast disintegrating tablets in mouth ar...
EFFECTS OF PH, SALT, TEMPERATURE ON CONVENTIONAL LIPOSOMES SIZE ENLARGEMENT ANALYZED BY OPTICAL MICROSCOPE
The objective of the present study was to investigate the effects of experimental conditions like pH, salt, temperature on the interactions of conventional liposomes. The model drug Stavudine was entrapped in the liposom...
REVIEW ON SPONSOR / APPLICANT MEETINGS WITH FDA: HIGHLIGHTS OF NEW GUIDANCE OVER EXISTING
The United States Department of Health and Human Services has a federal agency called the Food and Drug Administration (FDA or USFDA). A pre-planned assembling of two or more people who have been together for the purpose...
SIMULTANEOUS UV SPECTROPHOTOMETRIC METHODS FOR ESTIMATION OF CEFADROXIL AND PROBENECID IN TABLET DOSAGE FORM
Two methods for simultaneous estimation of Cefadroxil and Probenecid in combined tablet dosage form have been developed. The first UV spectrophotometric method was a determination using the simultaneous equation method a...
COMMON DEFICIENCIES RAISED BY VARIOUS REGULATORY AGENCIES
Timely Product registration is a challenge in today’s scenario. Regulatory agencies are keen in assessing CTD sections like redefining starting material of Drug substance manufacturing, Pharmaceutical development, impuri...